RESUMEN
OBJECTIVE: This study was conducted to investigate microRNA (miRNA) target regulations during the disease progression in laryngeal squamous cell carcinoma (LSCC) and identify biomarkers in different tumor stages. MATERIALS AND METHODS: The mRNA dataset GSE59102 and miRNA dataset GSE70289 were used in this study. After pretreatment, differentially expressed genes/miRNAs (DEGs/DEMs) in different tumor stages (beginning vs. margin, advanced vs. margin, and beginning vs. advanced) were selected on the basis of their limma package. Then, the enrichment analysis for these DEGs was conducted using ClueGO. Protein-protein interaction (PPI) network analysis was performed on the basis of the BioGRID database. After prediction of target genes of DEMs according to three validated miRNA databases, an integrated miRNA target network and its pathways were drawn using the multiMiR package. RESULTS: Numerous DEGs were identified in different tumor stages of LSCC (beginning vs. margin, advanced vs. margin, and beginning vs. advanced), and a set of 18 DEMs was identified. Cell cycle was the most significantly enriched pathway of the DEGs. Four hub nodes (MCM2, EGFR, CDK2, and CDK1) were highlighted in the PPI network. In the integrated miRNA target network, 2 miRNAs were predominant: hsa-miR-331-3p (2 predicted targets, E2F1 and TNFRSF10B) and has-miR-375 (1 predicted target, TNNI3). These genes were tied up with cell cycle or apoptosis pathway. CONCLUSIONS: Several genes and miRNAs might be used as markers for LSCC in different tumor stages (e.g., MCM2, EGFR, CDK1, CDK2, hsa-miR-331-3p, hsa-miR-375). They might function through the involvement of the cell cycle pathway.
Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias Laríngeas/genética , MicroARNs/genética , ARN Mensajero/genética , Carcinoma de Células Escamosas de Cabeza y Cuello/genética , Transcriptoma , Bases de Datos Genéticas , Perfilación de la Expresión Génica , Redes Reguladoras de Genes , Humanos , Neoplasias Laríngeas/patología , Estadificación de Neoplasias , Carcinoma de Células Escamosas de Cabeza y Cuello/patologíaRESUMEN
OBJECTIVE: To study the distribution of substance P-like immunoreactive fibers in feline temporomandibular joint. METHODS: The immunohistochemical PAP method was used for the investigation of the distribution of substance P-like immunoreactive fibers in feline temporomandibular joint. RESULTS: The TMJ capsule and the anterior and posterior disc attachments all contained SP-immunoreactive nerve fibers, but the medium fibers in diameter were mainly observed. The density of the distribution of SP-positive nerve fibers was the highest in the subsynovium of the TMJ capsule. The density of distribution was similar in the anterior and posterior disc attachments, but lower than in the subsynovium and the lateral joint capsule. Such fibers in the synovial membrane were sparser, and a part of the fibers were seen around the thin blood vessels in all the foregoing tissues. CONCLUSION: These results provide the morphological data for exploring the neurobiological mechanisms of temporomandibular joint disorder and its pain.
Asunto(s)
Autacoides/análisis , Fibras Nerviosas/patología , Péptidos/análisis , Sustancia P/análisis , Articulación Temporomandibular/inervación , Animales , Vasos Sanguíneos/inervación , Gatos , Femenino , Técnicas para Inmunoenzimas , Inmunohistoquímica , Péptidos y Proteínas de Señalización Intercelular , Cápsula Articular/inervación , Masculino , Membrana Sinovial/irrigación sanguínea , Membrana Sinovial/inervación , Articulación Temporomandibular/irrigación sanguínea , Disco de la Articulación Temporomandibular/inervaciónRESUMEN
Efficacy of an alternative combination chemotherapy with MMC, VCR, MTX, 5-FU, CDDP and ADM for adenocarcinoma of the lung is reported. Forty-one advanced cases (stage III: 9; IV: 32) were chosen for the chemotherapy. Two combination chemotherapies MMC + VCR + MTX + 5-FU + CDDP: MVMFP; MMC + VCR + MTX + 5-FU + ADM: MVMFA were repeated alternatively for 8 consecutive weeks with 2 interposed rest weeks, and this regimen was completed in 34 cases. All 41 cases were evaluable. Three and 26 cases achieved complete and partial responses, respectively. The response rate was 70.7%, and the median survival time was 13 months. The adverse effects of the chemotherapy observed were tolerable: alopecia (63.4%), gastrointestinal symptoms (14.5%), bone marrow toxicity (12.2%) and liver dysfunction (4.8%). These results indicate that our MVMFP/MVMFA alternative chemotherapy is quite effective for adenocarcinoma of the lung, comparable or superior to conventional chemotherapies.